Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the winners of its 12th annual Regeneron Prize for Creative Innovation. Christopher Giuliano and Julian Roessler, both Ph.D. candidates at MIT's Whitehead Institute for Biomedical Research, were awarded $50,000 each, plus a $10,000 grant for their institution. Six other finalists received $5,000 awards.
The Regeneron Prize recognizes outstanding early-career scientists in biomedical research. Nominees from leading U.S. research universities propose 'dream projects' evaluated on scientific merit, creativity, and originality. Since 2013, the program has supported early-career scientists with over $1.7 million in awards.
Regeneron's commitment to fostering the next generation of scientific innovators is evident in its broader STEM initiatives, which have supported over 2.4 million students since 2020 through various programs and competitions.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha annunciato i vincitori del suo 12° Regeneron Prize per l'Innovazione Creativa. Christopher Giuliano e Julian Roessler, entrambi dottorandi presso il Whitehead Institute for Biomedical Research del MIT, sono stati premiati con 50.000 dollari ciascuno, oltre a una sovvenzione di 10.000 dollari per la loro istituzione. Altri sei finalisti hanno ricevuto premi di 5.000 dollari.
Il Regeneron Prize riconosce gli scienziati emergenti straordinari nella ricerca biomedica. I candidati delle principali università di ricerca statunitensi propongono 'progetti da sogno' valutati in base al merito scientifico, alla creatività e all'originalità. Dal 2013, il programma ha supportato gli scienziati emergenti con oltre 1,7 milioni di dollari in premi.
L'impegno di Regeneron per promuovere la prossima generazione di innovatori scientifici è evidente nelle sue iniziative più ampie nel campo STEM, che hanno supportato oltre 2,4 milioni di studenti dal 2020 attraverso vari programmi e competizioni.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha anunciado los ganadores de su 12° Premio Regeneron a la Innovación Creativa. Christopher Giuliano y Julian Roessler, ambos candidatos a Ph.D. en el Whitehead Institute for Biomedical Research del MIT, fueron premiados con 50,000 dólares cada uno, además de una subvención de 10,000 dólares para su institución. Otros seis finalistas recibieron premios de 5,000 dólares.
El Premio Regeneron reconoce a destacados científicos en etapa temprana en la investigación biomédica. Los nominados de las principales universidades de investigación de EE. UU. proponen 'proyectos soñados' que se evalúan en función del mérito científico, la creatividad y la originalidad. Desde 2013, el programa ha apoyado a científicos en etapa temprana con más de 1.7 millones de dólares en premios.
El compromiso de Regeneron con el fomento de la próxima generación de innovadores científicos se refleja en sus iniciativas más amplias en STEM, que han apoyado a más de 2.4 millones de estudiantes desde 2020 a través de varios programas y competiciones.
레제너론 제약(NASDAQ: REGN)은 제12회 레제너론 창의 혁신상 수상자를 발표했습니다. 크리스토퍼 줄리아노와 줄리안 뢰슬러는 MIT의 화이트헤드 생물의학 연구소에서 박사 과정 중이며, 각각 50,000달러와 그들의 기관을 위한 10,000달러 보조금을 받았습니다. 여섯 명의 다른 결선 진출자는 5,000달러의 상을 받았습니다.
레제너온 상은 생물의학 연구에서 뛰어난 초기 경력 과학자를 인정합니다. 미국의 주요 연구 대학의 후보자들은 '꿈의 프로젝트'를 제안하며, 이는 과학적 우수성, 창의성 및 독창성에 따라 평가됩니다. 2013년 이후, 이 프로그램은 17만 달러 이상의 상금으로 초기 경력 과학자를 지원해왔습니다.
레제너온의 차세대 과학 혁신가 양성을 위한 노력이 2020년 이후로 240만 명 이상의 학생을 지원한 STEM 이니셔티브에서 분명하게 나타납니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a annoncé les lauréats de son 12e Prix Regeneron pour l'Innovation Créative. Christopher Giuliano et Julian Roessler, tous deux candidats au doctorat au Whitehead Institute for Biomedical Research du MIT, ont reçu chacun 50 000 dollars, ainsi qu'une subvention de 10 000 dollars pour leur institution. Six autres finalistes ont reçu des prix de 5 000 dollars.
Le Prix Regeneron reconnaît les scientifiques en début de carrière exceptionnels dans la recherche biomédicale. Les candidats des principales universités de recherche américaines proposent des 'projets de rêve' qui sont évalués sur la base du mérite scientifique, de la créativité et de l’originalité. Depuis 2013, le programme a soutenu des scientifiques en début de carrière avec plus de 1,7 million de dollars en prix.
L'engagement de Regeneron à promouvoir la prochaine génération d'innovateurs scientifiques est évident dans ses initiatives STEM plus larges, qui ont soutenu plus de 2,4 millions d'étudiants depuis 2020 à travers divers programmes et compétitions.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat die Gewinner des 12. Regeneron Preises für kreative Innovation bekannt gegeben. Christopher Giuliano und Julian Roessler, beide Doktoranden am Whitehead Institute for Biomedical Research des MIT, erhielten je 50.000 Dollar sowie einen Zuschuss von 10.000 Dollar für ihre Institution. Weitere sechs Finalisten erhielten Auszeichnungen in Höhe von 5.000 Dollar.
Der Regeneron Preis würdigt herausragende Wissenschaftler in der frühen Karriere in der biomedizinischen Forschung. Vorschläge für 'Traumprojekte' werden von Nominierten führender US-Forschungseinrichtungen eingereicht und hinsichtlich wissenschaftlicher Qualität, Kreativität und Originalität bewertet. Seit 2013 hat das Programm mehr als 1,7 Millionen Dollar an Preisen an aufstrebende Wissenschaftler vergeben.
Das Engagement von Regeneron zur Förderung der nächsten Generation wissenschaftlicher Innovatoren zeigt sich in den umfassenderen STEM-Initiativen, die seit 2020 über 2,4 Millionen Studierende durch verschiedene Programme und Wettbewerbe unterstützt haben.
- Regeneron continues to invest in future scientific talent through its annual Prize for Creative Innovation
- The company has awarded over $1.7 million to early-career scientists since 2013
- Regeneron's STEM initiatives have supported over 2.4 million students since 2020
- None.
TARRYTOWN, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 12th annual Regeneron Prize for Creative Innovation (the Regeneron Prize), an award that recognizes, celebrates and rewards outstanding talent and creativity from early-career scientists in biomedical research.
Each year, Regeneron asks leading research universities across the United States to nominate their top graduate students and postdoctoral fellows, who are then invited to conceptualize and propose "dream projects" within the realm of biomedical science. The finalists present their proposals to a selection committee comprised of Regeneron’s leading scientists who evaluate the projects based on scientific merit, creativity and originality.
This year’s winners are Christopher Giuliano and Julian Roessler, both Ph.D. candidates at the Massachusetts Institute of Technology’s (MIT) Whitehead Institute for Biomedical Research. Each has been awarded
“We launched the Regeneron Prize twelve years ago to help encourage and reward ‘blue sky’ thinking in biomedicine,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron. “Every amazing medical breakthrough that exists today — from a vaccine for polio, to a treatment for Ebola, to technologies that can edit genes within a patient’s body — was once just a crazy idea. Society needs more big ideas that could one day change lives, and these remarkable students have impressed and inspired us with their ability to think deeply, strategically and ambitiously.”
Christopher Giuliano, a Ph.D. candidate in Biology at MIT, is working in the laboratory of Dr. Sebastian Lourido at the Whitehead Institute. As an undergraduate, Christopher simultaneously researched biochemistry in Dr. Steve Glynn’s lab at State University of New York (SUNY) at Stony Brook and cancer biology in Dr. Jason Sheltzer’s lab at Cold Spring Harbor Laboratory in New York. Throughout his graduate career, he has pursued an interest in infectious disease and immunology studying the host response to Toxoplasma gondii, a parasite that causes toxoplasmosis. Christopher aims to repurpose the parasite's ability to manipulate muscle cells to improve the efficiency of muscle-directed gene therapies. Christopher’s Regeneron Prize winning proposal leveraged insights from his focused studies on infectious agents to enhance broader therapeutic strategies, aiming to revolutionize how we design treatments for complex diseases.
Julian Roessler, a Ph.D. candidate in Biology at MIT, is working in the laboratory of Dr. Siniša Hrvatin from the Whitehead Institute. Julian earned his BA in Biochemistry from the University of Pennsylvania, where he was a Vagelos Molecular Life Sciences Scholar. He completed a Master’s degree in Chemistry, also from the University of Pennsylvania, studying the heat shock response in ants with Dr. Shelley Berger. Since joining MIT, Julian has worked with Dr. David Sabatini studying the mTORC1 pathway before joining Dr. Hrvatin’s laboratory in 2021 to study the hypothalamic basis of torpor, a hypometabolic state. His research focuses on understanding the neurocircuitry and organ systems that coordinate responses to environmental challenges. Julian’s Regeneron Prize winning proposal applied ideas from his specialized research areas to broader systems, with the goal of understanding the brain circuitry required to deal with particular stressors to human survival.
"Regeneron's Prize encourages early career scientists to work independently to solve a problem that is important to them. We look for originality and creativity on the one hand, and practicality on the other," said David Glass, M.D., Vice President of Research and Chair of the Postdoctoral Program at Regeneron.
A key focus of Regeneron’s social impact work is to inspire and prepare young people to pursue STEM careers. As a company founded and led by physician-scientists, Regeneron is committed to fostering the next generation of scientific innovators who can help solve society’s greatest challenges. Since its inception in 2013, the Regeneron Prize has supported early-career scientists with more than
Requests for applications for the Regeneron Prize are distributed to academic institutions each December. Regeneron asks institutions to nominate two graduate students and two postdoctoral fellows. In addition to the dream project proposals, submissions must include a curriculum vitae and samples of publications that enable the selection committee to review each nominee's scholarly productivity. For more information, please email science.education@regeneron.com.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Media Contacts:
Joseph Brown, Regeneron
386-283-1323
Joseph.Brown2@regeneron.com
FAQ
Who won the 2024 Regeneron Prize for Creative Innovation?
How much is the Regeneron Prize for Creative Innovation award worth?
How many students has Regeneron's STEM initiatives supported since 2020?
What is the purpose of the Regeneron Prize for Creative Innovation?
How often is the Regeneron Prize for Creative Innovation awarded?
